Europe's Vaccine Candidate Pipeline is Loaded

Vaccines Europe recently published a pipeline review of its 14 member companies. The 2024 review includes information up to August 2024 and shows a promising vaccine pipeline to tackle today's and tomorrow's challenges.

This Vaccines Today review is excerpted and attached below:

Vaccination has revolutionized public health over the last century, saving countless lives and preventing long-term health complications caused by various pathogens. The benefits of vaccines go beyond individual protection.

Over the last 50 years, immunization efforts against 14 infectious diseases have saved over 154 million lives, with a significant proportion being infants. This achievement highlights immunization's crucial role in ensuring children survive their early years and grow into healthy adults.

The vaccine industry continues to evolve in response to the dynamic global health landscape, with innovation at its core.

From pioneering new vaccine technologies to expanding the scope of immunization strategies, the current pipeline reflects a 
commitment to saving as many lives as possible from infectious diseases.

Central to this vision is the concept of life-course immunization. 

Protecting health at every stage of life, from infancy through adulthood to older age, populations can remain healthy,  productive, and less susceptible to preventable diseases.

This review highlights the innovative approaches and collaborative efforts shaping the future of 98 vaccine candidates in the Vaccines Europe members' pipeline.

It underscores the importance of remaining competitive through cutting-edge research and streamlined and harmonized regulatory and access processes across the EU and its Member States.

By championing life-course immunization and fostering an innovative environment, we can ensure that Europe remains at the forefront of global health and economic prosperity.

Vaccine manufacturers remain committed to playing their part in ensuring a healthier tomorrow for entire populations.